AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and resp… Read more
AstraZeneca Pharma India Limited (ASTRAZEN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.082x
Based on the latest financial reports, AstraZeneca Pharma India Limited (ASTRAZEN) has a cash flow conversion efficiency ratio of -0.082x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹-657.30 Million) by net assets (₹7.99 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AstraZeneca Pharma India Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how AstraZeneca Pharma India Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AstraZeneca Pharma India Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca Pharma India Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Veken Elite
SHG:600152
|
0.043x |
|
Electrolux Professional AB (publ)
OTCGREY:ECTXF
|
0.102x |
|
Armada Hflr Pr
NYSE:AHH
|
0.032x |
|
Internacional de Cerámica S.A.B. de C.V
MX:CERAMICB
|
-0.016x |
|
Optics Technology Holding Co Ltd
SHE:300489
|
-0.012x |
|
PAR TECHNOLOGY DL-02
F:35U
|
N/A |
|
Gruppo MutuiOnline S.p.A.
LSE:0O2B
|
0.049x |
|
Djerriwarrh Investments Ltd
AU:DJW
|
0.018x |
Annual Cash Flow Conversion Efficiency for AstraZeneca Pharma India Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of AstraZeneca Pharma India Limited from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹7.70 Billion | ₹653.60 Million | 0.085x | +116.73% |
| 2024-03-31 | ₹7.12 Billion | ₹278.70 Million | 0.039x | -60.47% |
| 2023-03-31 | ₹5.89 Billion | ₹582.98 Million | 0.099x | -49.76% |
| 2022-03-31 | ₹5.11 Billion | ₹1.01 Billion | 0.197x | -14.19% |
| 2021-03-31 | ₹4.56 Billion | ₹1.05 Billion | 0.230x | -4.24% |
| 2020-03-31 | ₹3.64 Billion | ₹874.20 Million | 0.240x | +31.24% |
| 2019-03-31 | ₹3.01 Billion | ₹549.80 Million | 0.183x | +413.47% |
| 2018-03-31 | ₹2.47 Billion | ₹87.90 Million | 0.036x | -79.61% |
| 2017-03-31 | ₹2.18 Billion | ₹381.00 Million | 0.175x | -39.02% |
| 2016-03-31 | ₹1.99 Billion | ₹569.89 Million | 0.286x | +194.46% |
| 2015-03-31 | ₹1.51 Billion | ₹-457.01 Million | -0.303x | -6340.90% |
| 2014-03-31 | ₹1.72 Billion | ₹-8.08 Million | -0.005x | +92.22% |
| 2013-03-31 | ₹997.53 Million | ₹-60.36 Million | -0.061x | -129.58% |
| 2012-03-31 | ₹1.89 Billion | ₹387.27 Million | 0.205x | -43.00% |
| 2011-03-31 | ₹1.80 Billion | ₹645.01 Million | 0.359x | +59.27% |
| 2010-03-31 | ₹1.45 Billion | ₹325.71 Million | 0.225x | -67.94% |
| 2009-03-31 | ₹1.16 Billion | ₹816.48 Million | 0.703x | +181.59% |
| 2008-03-31 | ₹1.59 Billion | ₹397.06 Million | 0.250x | -35.23% |
| 2007-03-31 | ₹1.42 Billion | ₹546.21 Million | 0.385x | +74.53% |
| 2006-03-31 | ₹1.27 Billion | ₹280.88 Million | 0.221x | -58.58% |
| 2005-03-31 | ₹955.40 Million | ₹509.37 Million | 0.533x | -- |